摘要
骨髓增殖性疾病(myeloproliferative neoplasms, MPNs)是一群造血細胞自發性增生的疾病，前一次世界衛生組織(World Health Organization, WHO)對這類疾病的診斷標準及分類版本已經是2008年。隨著分子病理學的進步，美國病理醫學會(United States & Canadian Academyof Pathology, USCAP)於2015年的醫學年會上發布了相對應的增減修改。其中目前有建議修改診斷標準的疾病包含真性紅血球增多症(polycythemia vera, PV)、原發性骨髓纖維化(primarymyelofibrosis, PMF)、原發性血小板增多症(essential thrombocyhemia, ET)、慢性中性球白血病(chronic neutrophilic leukemia, CNL)。這些修改也預計會影響下一版世界衛生組織所發布各類骨髓增殖性疾病的診斷標準中，希望新的診斷標準及分類方法能對這群疾病在臨床上的實務使用性及診斷精確性有更好的協助。
參考文獻
Barbui T, Thiele J, Vannucchi AM, et al. Rethinking the diagnostic criteria of polycythemia vera. Leukemia 2014;28:1191-5."
Silver RT, Chow W, Orazi A, et al. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood 2013;122:1881-6."
Barbui T, Thiele J, Carobbio A, et al. Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol 2014;89:588-90."
Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014;124:2507-13"
Tefferi A, Wassie EA, Lasho TL, et al. Calreticulin mutations and long-term survival in essential thrombocythemia. Leukemia 2014;28:2300-3."